Keane-Myers A
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Twinbrook II Facility, Room 200E, 12441 Parklawn Drive, Rockville, MD 20852, USA.
Curr Allergy Asthma Rep. 2001 Nov;1(6):550-7. doi: 10.1007/s11882-001-0064-9.
The clinical presentation of the various forms of allergic conjunctivitis varies greatly from mild symptoms to severe disease with vision-threatening complications. Although an IgE-mediated type-1 hypersensitivity reaction has been demonstrated or postulated in many types of allergic eye disease, the pathophysiology underlying the allergic conjunctivitides is not fully understood. The variety of currently available treatment options underscores the complexity of the chemical reactions associated with mast cell degranulation and mediator release causing the onset of allergic signs and symptoms. Many of these treatments are merely palliative and do not eliminate the complex immune response initiating the symptoms, so there is a recurrence of disease as soon as the therapy is discontinued. Models of allergic eye disease have significantly aided the discovery of new anti-allergic and anti-inflammatory compounds that can be used safely in the eye.
各种形式的过敏性结膜炎的临床表现差异很大，从轻微症状到严重疾病并伴有威胁视力的并发症。尽管在许多类型的过敏性眼病中已证实或推测存在IgE介导的1型超敏反应，但过敏性结膜炎的病理生理学尚未完全了解。目前可用的多种治疗选择凸显了与肥大细胞脱颗粒和介质释放相关的化学反应的复杂性，这些反应导致了过敏体征和症状的出现。许多这些治疗仅仅是姑息性的，并没有消除引发症状的复杂免疫反应，因此一旦治疗停止，疾病就会复发。过敏性眼病模型极大地有助于发现可安全用于眼部的新型抗过敏和抗炎化合物。
